COMMUNIQUÉS West-GlobeNewswire
-
Axogen Completes Acquisition of BioCircuit Technologies, Adding NerveTape™, the First FDA Cleared Device for Sutureless Peripheral Nerve Repair
01/10/2026 -
Wandercraft Acquires Ekso Bionics, Uniting Two Pioneers to Advance and Expand Robotic Mobility
02/10/2026 -
Medicenna Announces Results of Annual General and Special Meeting of Shareholders
02/10/2026 -
New Drug Application Submission Initiated for Zipalertinib Plus Chemotherapy in First-Line EGFR Exon 20 Insertion Mutation NSCLC for Review Under FDA Real-Time Oncology Review Program
02/10/2026 -
Coloplast A/S - Major shareholder announcement
01/10/2026 -
Coloplast A/S - Trading in Coloplast shares by board members, executives or associated persons
01/10/2026 -
Nutraville Introduces Pineal Guardian Advanced, a Liquid Botanical Formula Designed to Support Pineal Gland and Cognitive Wellness
01/10/2026 -
Mangoceuticals Secures $2.5 Million Strategic Investment in MangoRx IP Holdings; Receives Initial $1.75 Million Tranche
01/10/2026 -
HealthEdge Launches Unified AI-Powered Platform to Guarantee Financial Outcomes for Health Plans
01/10/2026 -
Government of Saskatchewan proclaims October Health Literacy Month
01/10/2026 -
Michigan Contact Lens Opens 1-800-DRY-EYES Center in Expanded Southfield Facility
01/10/2026 -
Bloom Healthcare Brings Its Proven In-Home Care Model to Dallas-Fort Worth Seniors
01/10/2026 -
Phase 2 COURAGE Trial Confirms Trevogrumab Prevents Lean Mass and Muscle Loss During GLP-1 Receptor Agonist-induced Weight Loss
01/10/2026 -
FDA Grants Fast Track Designation for TRE-515 in Combination with KRAS G12C Inhibitors for the Treatment of Non-Small Cell Lung Cancer
01/10/2026 -
Ubamatamab (MUC16xCD3) Shows a High Rate of Durable Responses in Initial Study of Patients with Advanced Low-Grade Serous Ovarian Cancer (LGSOC)
01/10/2026 -
NMDP Gala Highlights Financial Challenges Facing Patients in Need of Blood Stem Cell Transplants
01/10/2026 -
IBA SA – NOTIFICATION TRANSPARENCE
01/10/2026 -
IBA – TRANSPARENCY NOTIFICATION
01/10/2026 -
Life Biosciences to Present First-in-Human Data from Ongoing Phase 1 Trial Evaluating ER-100 in Optic Neuropathies at Eyecelerator 2026
01/10/2026
Pages